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Clinical question: What is the best current disease-modifying therapy for relapsing–remitting 
multiple sclerosis?
Results: The evidence shows that the most effective disease-modifying therapy for delaying 
short- to medium-term disability progression, prevention of relapses, reducing the area and 
activity of lesions on magnetic resonance imaging, with the least side effects, is high-dose, 
high-frequency subcutaneous interferon-β1a 44 µg three times per week.
Implementation: The pitfalls in treatment of MS can be avoided by remembering the 
following points:
•  The most effective therapy to prevent or delay the appearance of permanent neurological 
disability with the fewest side effects should be chosen, and treatment should not be 
delayed.
•  Adherence to treatment should be monitored closely, and needs comprehensive patient 
information and education to establish long-term adherence, which is a critical determinant 
of long-term outcome.
•  The correct approach to the disease includes disease management, symptom manage-
ment, and patient management. A combination of tools is necessary to ease the various 
symptoms, which fall into three broad categories, i.e. rehabilitation, pharmacological, and 
procedural.
•  It is important to understand that no treatment modality should be used alone, unless it is 
in itself sufficient to remedy the particular symptom/problem.
Keywords: relapsing–remitting multiple sclerosis, interferon, disease-modifying therapy, 
relapse prevention
Multiple sclerosis
Definition: Multiple sclerosis (MS) is a debilitating autoimmune disease, although 
some new studies have raised the possibility that there is more than one pathway to the 
final pathological changes, and that different pathways may predominate in different 
clinical forms of MS.1 It has two major components, ie, axonal degeneration and 
inflammation, resulting in loss of the myelin-coated axons in the central nervous system 
(CNS).2 MS is most commonly seen in the adult Caucasian population of Western Euro-
pean ethnic origin,3 and most frequently affects women aged 20–40 years.4 A definite 
diagnosis of MS requires the occurrence of at least two neurological events consistent 
with demyelination that are separated both anatomically in the CNS and temporally.5
There are three clinical forms of the disease, the most common being the 
relapsing–remitting form (RRMS), which is characterized by episodes of neurological Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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impairment followed by complete or nearly complete recov-
ery.6 It has been shown that the systemic administration of 
interferon-beta-1a (IFNβ1a) decreases the frequency of 
exacerbations, slows the progression of physical disability, 
and reduces the development of brain lesions.7 IFNβ1a is 
a 166-amino acid glycoprotein with a molecular weight of 
approximately 22,500 Da. It is produced by recombinant 
DNA technology using genetically engineered Chinese 
Hamster Ovary cells into which the human IFNβ gene has 
been introduced.4,8
Prevalence: Globally, the median estimated prevalence of 
MS is 30 per 100,000, with a range of 5–80. Regionally, the 
median estimated prevalence of MS is highest in Europe at 
80 per 100,000, followed by the Eastern Mediterranean (14.9 
per 100,000), and the US (8.3 per 100,000). The countries 
reporting the highest estimated prevalence of MS are Hun-
gary (176 per 100,000), Slovenia (150), Germany (149), and 
the US (135).9 The total estimated female:male ratio is around 
2.0, and the prevalence rates reported are higher for women.10 
Other studies in the US have reported a prevalence of 58–95 
per 100,00.11 Moreover, in the past 25 years, prevalence stud-
ies of specific US regions have produced a range of estimates, 
up to 177 per 100,000 in Olmstead County, Minnesota.12
Incidence: Globally, the median incidence of MS is 2.5 per 
100,000. Regionally, the median estimated incidence of MS is 
greatest in Europe (3.8 per 100,000), followed by the Eastern 
Mediterranean (2), and the US (1.5). The countries reporting 
the highest estimated incidence of MS include Croatia (29), 
Iceland (10), and Hungary (9.8).9
Economics: From the perspective of the US health care 
payer, and considering only the direct medical costs, the cost 
per relapse is close to 4700 USD, and the cost per disability 
progression step is nearly 1800 USD. Subcutaneous (SC) 
IFNβ1a injection, and glatiramer acetate had the most 
favorable costs per relapse avoided, and intramuscular (IM) 
IFNβ1a injection had the least favorable cost-effectiveness 
ratio (∼ 142,000 USD per relapse avoided), in a two-year 
follow-up period, according to Goldberg et al.13 In other 
study,14 SC IFNβ1a was predicted to enable more patients 
to avoid relapse. Total mean costs per patient (discounted) 
were ∼ 80,000 USD with SC IFNβ1a versus ∼ 74,000 USD 
with IM IFNβ1a administration, representing a net increase 
of 5400 USD per patient.
Levels of evidence: Systematic reviews, randomized clini-
cal trials (RCTs), and general reviews.
Search sources: Medline (PubMed), Cochrane Library, The 
Cochrane Multiple Sclerosis Review Group NHS evidence 
(UK), DARE, EMBASE.
Outcomes: The major outcomes seen in most reports 
were delayed disability progression, prevention of relapses, 
reduced magnetic resonance imaging (MRI) lesion activity 
and area, decreasing side effects, long-term effects, and 
tolerability.
Consumer summary: MS may be related to the immune 
system. IFNs have several effects on the immune system, 
and act against viruses. IFN can help to reduce disability 
and exacerbations for people with MS in the medium term. 
IFNβ1a administered IM or SC can lead to a moderate 
reduction in recurrences and disability in MS patients with 
remissions. The most common side effects are influenza-like 
symptoms, injection site reactions, pain in the joints and 
muscles, fatigue, and headache.
The evidence
Systematic reviews: 10
RCTs: 12
Systematic reviews
First-line treatment of RRMS is currently based on 
immunomodulatory drugs, including recombinant IFNβ1a 
and IFNβ1b or glatiramer acetate, although the latter has 
been shown to be only modestly effective. Recently it has 
been suggested that nerve damage and inflammation are early 
events in MS evolution which immunomodulatory drugs can 
only partially prevent. This paper makes a critical comparison 
between the main treatments15–29 used in MS, to determine if 
IFNβ1a is the best treatment.
interferon-β1a
It has been hypothesized that the efficacy of IFN could be 
higher if it is used at the first appearance of symptoms, in 
Clinically Isolated Syndromes suggestive of demyelinating 
events, a pathology which carries a high risk of conversion 
to clinically definite MS. The efficacy of IFNβ1a for exac-
erbations and disease progression in patients with RRMS 
was modest after one and two years of treatment. IFN 
administered by the oral route was not effective for prevention 
of relapses. Longer follow-up and more uniform reporting of 
clinical and MRI outcomes in these trials might have allowed 
for more convincing conclusions.15 Other research confirmed 
the efficacy of IFNβ1a in preventing the conversion from a Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Clinically Isolated Syndrome to clinically definite MS over 
two years of follow-up. It could be useful for clinical practice 
if future analyses of the efficacy of IFNβ1a treatment were 
undertaken in different patient subgroups, because patients 
in the studies reported to date have been clinically heteroge-
neous in terms of length of follow-up and clinical findings 
at the time of initial presentation.16
Glatiramer acetate
A Cochrane systematic review performed in 2003 concluded 
that glatiramer acetate did not show any beneficial effect on 
the main outcome measures in MS, and did not substantially 
affect the risk of clinical relapses. Therefore, its routine use 
in clinical practice was not supported.17 Nevertheless, the 
ongoing US glatiramer acetate trial is the longest evaluation 
of continuous sole disease-modifying therapy in RRMS. 
It has been concluded18 that MS patients with a mean disease 
duration of 22 years who were treated with glatiramer acetate 
for up to 15 years had reduced relapse rates, and decreased 
disability progression and transition to secondary progressive 
MS. There were no long-term safety issues. Patients with 
MS who have an unsatisfactory response to IFNβ should be 
considered for glatiramer acetate therapy.18
Natalizumab
An immunosuppressive drug, natalizumab was previously 
available for a short period of time for treatment of MS in 
the US. It was consistently more effective than placebo for 
both relapse-related outcomes and disease progression in 
two trials.19 One of those trials included IM IFNβ1a used 
concomitantly with natalizumab and placebo arms; however, 
this did not appear to impact the findings of that trial in terms 
of efficacy outcomes. Natalizumab was initially suspended as 
a result of several confirmed cases of progressive multifocal 
leukoencephalopathy.19 The exact relationship between mul-
tifocal leukoencephalopathy and natalizumab is unknown. 
However, in 2005, the manufacturers suspended the supply 
of this drug from commercial distribution.20 After lengthy 
deliberation by an FDA advisory panel, natalizumab was 
reapproved in 2009, but with stringent restrictions including 
patient, provider, and site registration.21 It is now considered 
as second-line therapy for patients who had failed first-line 
agents, i.e. IFN or glatiramer acetate.
intravenous immunoglobulins
There is evidence to support the use of intravenous immu-
noglobulins (IVIG) as a preventative treatment for relapses 
in RRMS. There was no evidence of delay in progression of 
disease in secondary progressive MS,22 but this needs to be 
evaluated carefully in relapsing–remitting disease.
Mitoxantrone
This agent has partial efficacy, but due to its unclear 
long-term safety profile, it should be reserved for patients 
with worsening RRMS and evidence of worsening dis-
ability.23 Limited evidence from one small trial showed 
that mitoxantrone was more effective than placebo for both 
disease progression and relapse rates.23
Azathioprine
Azathioprine is a reasonable alternative to IFNβ1a for 
treating MS. A logical next step for future trials would seem 
to be a direct comparison of azathioprine and IFNβ1a, which 
has yet to be done.24 Better evidence of the effects of this 
drug is needed.
Aminopyridines
These agents are possibly useful for treating MS symptoms, 
although the available information does not allow any objective 
statement about their safety or efficacy. Publication bias remains 
a pervasive problem in this area, and until the results of as yet 
unpublished studies are available to the scientific community, 
no confident estimate of the effectiveness of the aminopyridines 
in the management of MS symptoms is possible.25
cyclophosphamide
Cyclophosphamide is an immunosuppressive drug used for 
various autoimmune diseases, although its use for MS has 
not been well studied. In the pertinent literature, there are 
scant data available to show that cyclophosphamide slows MS 
progression in the medium term. It has been noted that side 
effects, including alopecia, nausea, vomiting, and amenorrhea 
occur at high frequency, and there is also evidence to suggest 
adverse effects appearing after two years of treatment.26
Methotrexate
The only study of methotrexate in progressive MS revealed a 
nonsignificant trend in sustained reduction of disease progres-
sion on the Expanded Disability Status Scale and number of 
relapses in favor of methotrexate. However, as yet, there are 
not enough studies of methotrexate in RRMS to reach any 
firm conclusions.27
Hyperbaric oxygen therapy
This treatment modality involves people breathing pure 
oxygen in a specially designed chamber. Hyperbaric oxygen Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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therapy has sometimes been used for MS, especially in cases 
of lack of oxygen to the affected nerves leading to worsen-
ing MS, but this theory is unproven. There is no consistent 
evidence to confirm a beneficial effect of hyperbaric oxygen 
therapy for the treatment of MS, and its routine use is not 
justified. The analyses suggestive of benefit were isolated, 
biologically implausible, and would need to be confirmed in 
well-designed trials in the future.28
Other therapies
Emerging immunosuppressive therapies in oncology and organ 
transplantation have been associated with life-threatening 
risks, including serious opportunistic infections and/or new 
malignancies.39 Among these drugs are cladribine, alemtu-
zumab, rituximab, and fingolimod. With alemtuzumab, the 
greatest risk seems to be the development of autoimmune 
syndromes. The effects of cladribine, alemtuzumab, and 
rituximab on the immune system are more long term, and 
must be monitored years rather than for days or weeks. Other 
drugs, such as laquinimod and dimethyl fumarate, appear to be 
largely immunomodulatory, whereas teriflunomide is mainly 
immunosuppressive, i.e. preventing lymphocyte proliferation. 
Laquinimod, dimethyl fumarate, and teriflunomide are not 
associated with these life-threatening risks, and they seem to 
be safer. However, some questions remain about how robust 
the efficacy of these therapies will be.39,40 There are not enough 
systematic reviews supporting evidence on the effect of dacli-
zumab, amtuzumab, and alemtuzumab in RRMS.29 Alternative 
therapies, including bone marrow autologous transplantation 
and plasmapheresis, did not showed definitive results neither. 
A number of small clinical trials24–27 supported the modest 
effect of IVIG, azathioprine, methotrexate, and cyclophosph-
amide, either alone or in combination with standard therapy.
Randomized clinical trials
Twelve RCTs were found4,8,33,47–54 and their results are shown 
in the Table 1.
Sc iFNβ1a versus Sc iFNβ1b
IFNβ1a has shown better outcomes in RRMS, causing fewer 
side effects and less immunogenicity. SC IFNβ1a and SC 
IFNβ1b were similarly effective in reducing the frequency 
of relapses and slowing disease progression, whereas IM 
IFNβ1a was less effective. However, these findings were con-
tradicted by trials which compared each drug with placebo. 
IM IFNβ1a was similar to IFNβ1b for preventing relapses, 
while SC IFNβ1b was not significantly better than placebo 
for slowing disease progression.
iFNβ1 used alone or as combination therapy
There was weak evidence showing that IFNβ1a in combina-
tion with other drugs increases favorable outcomes in MS. 
Many preliminary studies have produced favorable results for 
various combination regimens. For instance, add-on, high-
dose daclizumab treatment reduces the number of new or 
enlarged gadolinium contrast-enhancing lesions, and might 
reduce MS disease activity to a greater extent than IFNβ1a 
alone,29 and oral methylprednisolone given in pulses every 
four weeks as an add-on therapy to SC IFNβ1a in patients 
with RRMS led to a significant reduction in relapse rate.30 
However, several subsequent large, randomized, controlled 
trials have had negative or conflicting results.31 Therefore, 
the usefulness of combination therapy in MS remains 
uncertain.
Subcutaneous versus intramuscular iFNβ1
There is no clear evidence that the SC route is better than 
the IM route, although tolerability problems, especially 
related to injections and injection site reactions with the IM 
route (including lipoatrophy), continue to be an important 
issue. However, in general terms, the SC route has had bet-
ter acceptance by patients and the most favorable adherence 
to treatment. Two trials suggested a benefit of SC IFNβ1a 
over interferon IM IFNβ1a in terms of relapse outcomes. In 
addition, another study has shown that SC IFNβ1 had dose-
dependent cognitive benefits in mildly disabled patients with 
RRMS, and supported the idea of early initiation of high-dose 
IFNβ1a treatment.32 On the other hand, the ASSURANCE 
study concluded that for some patients with MS, long-term 
use of IM IFNβ1a was associated with significantly less 
disability progression, better quality of life, and greater 
independence in activities of daily living.33 Therefore, the 
only real, but weak, difference between the SC and IM routes 
would be acceptance and convenience for patients.
Optimal duration of effect of iFNβ1
One RCT showed that SC IFNβ1a would yield greater health 
benefits over four years than IM IFNβ1a, at a cost that would 
seem to be a reasonable trade-off. In the long term, IM 
IFNβ1a also showed a beneficial safety-tolerability profile. 
IM IFNβ1a was well tolerated, and no new safety concerns 
were identified over 15 years of use. 33 Despite that, there 
have not been enough trials that show significant beneficial 
effects in delaying disability progression with long-term 
therapy (over 20 years or more), with any of the IFNs. The 
methodological difficulties faced in designing a trial of such 
an extended duration would be hard to overcome.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Low- versus high-dose iFN therapy
SC IFNβ1a 44 µg has shown the highest efficacy in the treat-
ment of RRMS.34 Long-term Class 1 data from PRISMS 
supported the use of SC IFNβ1a twice weekly as a first-line 
treatment for MS, as evidenced by sustained efficacy rates, 
acceptable safety profiles, and high patient adherence rates.34
Frequency of administration
SC IFNβ1a demonstrated better outcomes in RRMS at a dosing 
frequency of three times per week. Two RCTs concluded that 
administering high-dose, high-frequency SC IFNβ1a was 
more effective in preventing relapses in patients with RRMS 
than low-dose weekly IM IFNβ1 after 64 weeks.34,35
iFNβ1 versus glatiramer acetate
Both these drugs have been used as first-line treatment for 
RRMS in RCTs. The mean difference in relapse rate between 
glatiramer acetate and placebo was statistically significant 
in some trials, but the effect on disease progression was 
unclear.37 Adverse events rates were higher for glatiramer 
acetate than for placebo, most notably post-injection systemic 
reactions and injection site reactions, as were withdrawals 
due to adverse events. Withdrawal rates were also consis-
tently significantly higher in observational studies when 
compared with placebo. The use of glatiramer acetate in 
cases of suboptimal response to IFNs appeared to improve 
the effectiveness of the latter. However, IFNβ1 has showed 
better results than glatiramer acetate in most cases.
Suboptimal responses
The frequency of suboptimal responses to MS therapy was as 
high as 30% in the three years following initiation of first-line 
therapies.36 Criteria for defining a suboptimal response vary 
between the trials. Typical criteria include relapse rates greater 
than one per year or unchanged from pretreatment rates, 
incomplete recovery from relapses, new brainstem or spinal 
cord lesions, and progression of disability or cognitive impair-
ment that leads to a disruption in activities of daily living. 
There are at least three main causes of suboptimal responses.37 
These are development of neutralizing antibodies (NABs) 
that reduce or abolish IFNβ bioactivity in a titer-dependent 
manner, lack of long-term adherence to therapy, and, possibly, 
switching of disease-modifying therapies to improve patient 
response or eliminate adverse effects.
Adherence to therapy
Lack of adherence was shown in some RCTs. Notably, four of 
the six currently available therapies require self-injection, and Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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all have side effects ranging from influenza-like symptoms to 
injection site reactions. Barriers to adherence included needle 
phobia, not taking medication because of forgetfulness, 
complacency, treatment fatigue, changes in socioeconomic 
status, and perceived lack of efficacy.36 The most common 
adverse events overall were injection site reactions, 
vasodilatation, rash, dyspnea, and chest pain. Localized 
lipoatrophy occurred in roughly 2% of patients.37
Neutralizing antibodies
Some reports38,39 showed that the appearance of high-titer 
(, 1:100) neutralizing NABs totally blocked the biological 
activity of IFNβ. The development of NABs did occur in 
The Practice
Avoiding pitfalls
•	 The most effective therapy with the least side effects 
should be started as soon as possible to prevent or 
delay the appearance of permanent neurological 
disability
•	 Adherence to treatment should be monitored closely, 
and comprehensive patient information and education is 
necessary to establish long-term adherence, which is a 
critical determinant of long-term outcome.
•	 The best approach to treatment of the disease includes 
disease management, symptom management, and patient 
management. A combination of tools is necessary to 
ease the various symptoms that fall into three broad 
categories, i.e. rehabilitation, pharmacological, and pro-
cedural. It is important to understand that none of these 
treatment approaches should be used in isolation, unless 
it is by itself sufficient to remedy the particular symptom/
problem.
Management
Patients who have an unsatisfactory response to IFNβ1 
should be considered for glatiramer acetate therapy. This 
should be started early in the course of MS to minimize 
irreversible axonal damage. Patients with worsening MS 
may be referred for mitoxantrone therapy, but short- and 
long-term adverse effects, including cardiotoxicity, must 
be monitored for closely. To shorten the duration of MS 
relapses and accelerate recovery, corticosteroid therapy 
should be considered. MRI should be repeated every three 
months after a clinically suspicious episode to facilitate early 
diagnosis of MS.
Assessment
Magnetic resonance imaging of brain
MRI scan of the brain is the most useful test for confirming 
the diagnosis of MS. The lesions appear as areas of high 
signal, predominantly in the cerebral white matter or spinal 
cord, on T2-weighted images.41
Multimodal evoked potentials
Multimodal evoked potentials may be useful for demonstrating 
the presence of subclinical lesions in sensory pathways. 
The presence of three abnormal multimodal evoked 
potentials increases the risk of reaching moderate disability 
independently of baseline MRI.42
Cerebrospinal fluid analysis
The CSF immunoglobulin G concentration is increased 
relative to other CSF proteins (eg, albumin), and CSF gel 
electrophoresis reveals oligoclonal bands that are not present 
in a matched serum sample.43
Local physical findings
Some symptoms could be explained by localized disease: the 
presence of steadily progressive disease, the absence of clinical 
remission, the absence of oculomotor, optic nerve, sensory, 
or bladder involvement, and normal CSF findings. However, 
none of these findings exclude the diagnosis of MS.44
Treatment
The evidence shows that the most effective disease-modifying 
therapy at this time is high-dose, high-frequency SC IFNβ1 
(44 µg three times per week alone). The major difference 
between the IFNβ1 drugs is that IM IFNβ1a is given once 
up to 35% of IFNβ-treated patients, with several studies 
suggesting that IFNβ1b was most immunogenic (35% of 
patients NAB-positive), followed by subcutaneous IFNβ1a 
(23.7% of patients NAB-positive), and, lastly, IM IFNβ1a 
(7% of patients NAB-positive).40
Conclusions
Thus far, the evidence shows that the most effective short- 
to medium-term, disease-modifying therapy for delaying 
disability progression, prevention of relapses, reducing the 
area and activity of lesions seen on MRI, with the least side 
effects, is high-dose, high-frequency SC IFNβ1a 44 µg three 
times per weekNeuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Table 2.  current drugs used in relapsing–remitting multiple sclerosis.
Drug Brand name Delivery systems Dosage Side effects  Monitoring
iFNβ-1a (iM)  Avonex® reconstitution  
needed/prefilled syringe
30 µg iM once  
weekly
Influenza-like symptoms cBc, LFTs
iFNβ-1a (Sc) rebif® Ready to use prefilled syringe 22–44 µg Sc three  
times weekly
Influenza-like symptoms and  
injection site reactions
cBc, LFTs
iFNβ-1b (Sc) Betaseron® reconstitution needed 0.25 mg Sc every  
other day
Influenza-like symptoms and  
injection site reactions; 
cBc, LFTs
Glatiramer acetate copoxone® Ready to use prefilled syringe 20 mg Sc once daily injection site reactions and a  
benign systemic reaction  
(flushing, chest tightness with  
racing or pounding  
heartbeat, anxiety, and  
difficulty in breathing)
Local site of 
injection
Mitoxantrone  
(immunosuppressive)
Novantrone® injection concentrate supplied,  
dilution required
5 to 12 mg per m2  
iv every 3 months
Mild chemotherapy-related  
side effects, cumulative  
cardiotoxicity, small  
increased risk of leukemia
cBc,  
cardiological  
assessment
Abbreviations: iFN, interferon; iM, intramuscular; Sc, subcutaneous; iv, intravenous; cBc, complete blood count; LFTs, liver function tests.
a week and SC IFNβ1a and IFNβ1b are given three times a 
week, or every other day, respectively. The main differences 
between the available immunomodulatory drugs are shown 
in Table 2. Treatment with any IFNβ agent can result in the 
development of NABs. Although study results are variable, 
once-weekly IM IFNβ1a therapy has been reported to have 
the lowest incidence of NAB development.46
Symptomatic therapy
There is no clear evidence that symptomatic therapy is useful 
for all patients. Response is dependent on the stage of the dis-
ease and on the affective and psychiatric status of the patient, 
although some medications can be used to improve symptoms 
partially.44–46 Influenza-like symptoms, including fever, chills, 
malaise, muscle pain, and fatigue are the most common 
side effects, and usually dissipate with continued therapy 
and premedication with a nonsteroidal anti-inflammatory 
drug. Dose titration at the initiation of IFNβ therapy is also 
a useful strategy. Other side effects of IFNβ include injection 
site reactions, depression, mild anemia, thrombocytopenia, 
elevated transaminase levels, and worsening of pre-existing 
spasticity. These are not usually severe and rarely lead to 
discontinuation of treatment.45
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